NanoViricides Plans Next Phase of Clinical Trials for Broad-Spectrum Antiviral NV-387

SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) has announced plans to advance its antiviral drug candidate NV-387 to Phase II clinical trials. NV-387 has demonstrated effectiveness against several major respiratory viruses, including COVID-19, Influenza, RSV, and Bird Flu, in animal models.

Recent outbreaks of viruses such as MPox, Bird Flu, and COVID-19 emphasize the need for broad-spectrum antiviral treatments. NV-387 aims to address this issue by providing a single drug solution for multiple viral infections, potentially simplifying pandemic preparedness and reducing drug development costs.

NV-387 has completed Phase I clinical trials with no reported adverse events, indicating a strong safety profile. The drug showed superior activity compared to approved treatments and has protected animal models from lung damage caused by viral infections.

NanoViricides is now preparing for Phase II trials to evaluate NV-387 for various indications, including RSV, Influenza, and COVID-19. The company is committed to following the fastest regulatory path to obtain approvals in the USA and other countries.